Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4622762 | 1.00 | L3MBTL1 (0.45) | L3MBTL1SLC40A1GLO1KDM4EPKM | |
| SCHEMBL578901 | 0.82 | L3MBTL1 (0.51) | L3MBTL1SLC40A1GLO1KDM4EPKM | |
| SCHEMBL20094824 | 0.79 | L3MBTL1 (0.49) | L3MBTL1SLC40A1GLO1KDM4EPKM | |
| SCHEMBL21151495 | 0.75 | SMN1; SMN2 (0.53) | L3MBTL1KDM4EMMP2 | |
| SCHEMBL23036706 | 0.75 | L3MBTL1 (0.51) | L3MBTL1SLC40A1GLO1KDM4EPKM | |
| SCHEMBL27476059 | 0.74 | L3MBTL1 (0.44) | L3MBTL1SLC40A1GLO1KDM4EPKM | |
| SCHEMBL7473562 | 0.74 | L3MBTL1 (0.44) | L3MBTL1SLC40A1GLO1KDM4EPKM | |
| SCHEMBL2371864 | 0.72 | L3MBTL1 (0.56) | L3MBTL1SLC40A1GLO1KDM4EPKM | |
| SCHEMBL29706147 | 0.72 | L3MBTL1 (0.56) | L3MBTL1SLC40A1GLO1KDM4EPKM | |
| SCHEMBL762825 | 0.72 | L3MBTL1 (0.56) | L3MBTL1SLC40A1GLO1KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262224-A1 | Method of Preparation of Benzofuran-2-Carboxylic Acid -Amide | SMITHKLINE BEECHAM CORPORATION | 2008-10-23 | — | — | US | claimed |
| EP-1713790-A2 | METHOD OF PREPARATION OF BENZOFURAN-2-CARBOXYLIC ACID (S)-3-METHYL-1- ((4S, 7R)-7METHYL-3-OXO-1-(PYRIDINE-2-SULFONYL)-AZ EPAN-4-YLCARBAMOYL-BUTYL)-AMIDE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2005069981-A2 | METHOD OF PREPARATION OF BENZOFURAN-2-CARBOXYLIC ACID {(S)-3-METHYL-1-[(4S, 7R)-7METHYL-3-OXO-1-(PYRIDINE-2-SULFONYL)-AZEPAN-4-YLCARBAMOYL]-BUTYL}-AMIDE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-04 | — | — | WO | claimed |
| US-20080262224-A1 | Method of Preparation of Benzofuran-2-Carboxylic Acid -Amide | SMITHKLINE BEECHAM CORPORATION | 2008-10-23 | — | — | US | disclosed |
| EP-1713790-A2 | METHOD OF PREPARATION OF BENZOFURAN-2-CARBOXYLIC ACID (S)-3-METHYL-1- ((4S, 7R)-7METHYL-3-OXO-1-(PYRIDINE-2-SULFONYL)-AZ EPAN-4-YLCARBAMOYL-BUTYL)-AMIDE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005069981-A2 | METHOD OF PREPARATION OF BENZOFURAN-2-CARBOXYLIC ACID {(S)-3-METHYL-1-[(4S, 7R)-7METHYL-3-OXO-1-(PYRIDINE-2-SULFONYL)-AZEPAN-4-YLCARBAMOYL]-BUTYL}-AMIDE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262224-A1 | Method of Preparation of Benzofuran-2-Carboxylic Acid -Amide | ACMSD, CPS1, BCAT2 | L3MBTL1 4254/4885SLC40A1 4429/4885GLO1 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.